title: Oncological Outcomes and Complications After Volume Replacement Oncoplastic Breast Conservations-The Glasgow Experience.
abstract: BACKGROUND
  Oncoplastic breast conservation surgery (OBCS) combines the principles of surgical oncology and plastic surgery. OBCS has now become a growing option for the treatment of breast cancer and forms a part of breast-conserving therapy (BCT). We sought to investigate and report our experience in two breast units in Glasgow (Victoria Infirmary and Western Infirmary) on volume replacement OBCS.
  
  
  METHODS
  Details of patients treated with volume replacement OBCS were identified from a prospectively recorded database from November 2010 to October 2015. The clinical records included in the oncoplastic dataset were analyzed for demographics, tumor, treatment characteristics, and recurrences. The data were analyzed for follow-up to determine the pattern and timing of recurrence up to April 2016. The primary outcome of this study was tumor-free margin resection rates, and the secondary outcomes were locoregional and distant recurrence rates as these correlate with the overall oncological safety of volume replacement oncoplastic breast surgery (OPBS).
  
  
  RESULTS
  A total of 30 volume replacement oncoplastic breast conservation procedures have been carried out in this time period. The mean age of the former group was 51 years. Twice as many patients presented symptomatically than had tumors detected on screening. The mean preoperative tumor size on radiology was 25.4 mm. Patients underwent 13 thoracoepigastric flaps, 5 lateral intercostal artery perforator (LICAP) flaps, 2 thoracodorsal artery perforator (TDAP) flaps, 1 lateral thoracic artery perforator (LTAP) flap, 1 crescent flap volume replacement surgery, and 8 matrix rotations. Two patients had neoadjuvant chemotherapy. Fourteen patients had adjuvant chemotherapy, and all patients were treated with adjuvant radiotherapy. Twenty-two patients were treated with hormonal therapy and four patients were treated with Herceptin. The rate of incomplete excision was 10%. Median follow-up time was 48.5 months. Only one regional recurrence was detected. Eight patients encountered some form of complication.
  
  
  CONCLUSIONS
  This study continues to show the relative oncological safety of volume replacement oncoplastic conservations as an option for reconstruction in breast cancer patients. Further research is urgently needed to build robust evidence supporting the long-term oncological safety.
authors.affiliation: The New Victoria Infirmary, Glasgow, Scotland, UK.
authors.forename: Weiguang
authors.initials: W
authors.lastname: Ho
authors.affiliation: Gartnavel General Hospital, Glasgow, Scotland, UK.
authors.forename: Sheila
authors.initials: S
authors.lastname: Stallard
authors.affiliation: Gartnavel General Hospital, Glasgow, Scotland, UK.
authors.forename: Julie
authors.initials: J
authors.lastname: Doughty
authors.affiliation: Queen Elizabeth University Hospital, Glasgow, Scotland, UK.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Mallon
authors.affiliation: The New Victoria Infirmary, Glasgow, Scotland, UK.
authors.forename: Laszlo
authors.initials: L
authors.lastname: Romics
keywords: complication; oncoplastic; recurrence; therapeutic mammaplasty; volume replacement